360 related articles for article (PubMed ID: 34476650)
81. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
82. Germline Genetic Features of Young Individuals With Colorectal Cancer.
Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
[TBL] [Abstract][Full Text] [Related]
83. Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.
Shin HC; Lee HB; Yoo TK; Lee ES; Kim RN; Park B; Yoon KA; Park C; Lee ES; Moon HG; Noh DY; Kong SY; Han W
Cancer Res Treat; 2020 Jul; 52(3):697-713. PubMed ID: 32019277
[TBL] [Abstract][Full Text] [Related]
84. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
85. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
86. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract][Full Text] [Related]
87. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
88. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.
Hsu FC; Roberts NJ; Childs E; Porter N; Rabe KG; Borgida A; Ukaegbu C; Goggins MG; Hruban RH; Zogopoulos G; Syngal S; Gallinger S; Petersen GM; Klein AP
JAMA Oncol; 2021 Nov; 7(11):1664-1668. PubMed ID: 34529012
[TBL] [Abstract][Full Text] [Related]
89. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
[TBL] [Abstract][Full Text] [Related]
90. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
[TBL] [Abstract][Full Text] [Related]
91. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
92. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
93. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
[TBL] [Abstract][Full Text] [Related]
94. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
95. Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
Hampel H; Yurgelun MB
J Clin Oncol; 2022 Aug; 40(24):2681-2692. PubMed ID: 35649230
[TBL] [Abstract][Full Text] [Related]
96. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
[TBL] [Abstract][Full Text] [Related]
97. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Lowery MA; Wong W; Jordan EJ; Lee JW; Kemel Y; Vijai J; Mandelker D; Zehir A; Capanu M; Salo-Mullen E; Arnold AG; Yu KH; Varghese AM; Kelsen DP; Brenner R; Kaufmann E; Ravichandran V; Mukherjee S; Berger MF; Hyman DM; Klimstra DS; Abou-Alfa GK; Tjan C; Covington C; Maynard H; Allen PJ; Askan G; Leach SD; Iacobuzio-Donahue CA; Robson ME; Offit K; Stadler ZK; O'Reilly EM
J Natl Cancer Inst; 2018 Oct; 110(10):1067-1074. PubMed ID: 29506128
[TBL] [Abstract][Full Text] [Related]
98. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition.
Kamihara J; Zhou J; LaDuca H; Wassner AJ; Dalton E; Garber JE; Black MH
Cancer Med; 2022 Apr; 11(8):1745-1752. PubMed ID: 35174967
[TBL] [Abstract][Full Text] [Related]
99. Personalized Systemic Therapies in Hereditary Cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract][Full Text] [Related]
100. Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing.
Wang X; Kaneko K; Arakawa H; Habano E; Omi M; Nakashima E; Kawachi H; Tonooka A; Omatsu K; Nomura H; Yunokawa M; Kanao H; Takahashi S; Nakajima T; Ueki A
Case Rep Oncol; 2022; 15(2):792-797. PubMed ID: 36157696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]